Quince Therapeutics, Inc. (NASDAQ:QNCX ) Analyst/Investor Day October 2, 2025 10:00 AM EDT Company Participants Dirk Thye - CEO, Chief Medical Officer & Director Giovanni Mambrini - Chief Technology Officer Caralee Schaefer Pamela Williamson - Head of Regulatory Affairs Charles Ryan - President Brendan Hannah - Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Acco...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adul...
Quince Therapeutics, Inc. - Special Call Company Participants Dirk Thye - CEO, Chief Medical Officer & Director Brendan Hannah - Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer Conference Call Participants Andrew Fein - H.C. Wainwright & Co, LLC, Research Division Presentation Andrew Fein H.C.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host a virtual Investor Day on Thursday, October 2, 2025, from 10:00 a.m. and 12:00 p.m. Eastern Time. Quince's virtual Investor D...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate at the H.C. Wainwright 27th Annual Global Investment Conference...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2025. Dirk Thye, M.D., Quin...
SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation's largest independent ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.